Global Invasive Fungal Infection (IFI) Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)
EXECUTIVE SUMMARY
Global Invasive Fungal Infection Market was valued at USD 6103.5 Million in the year 2018. The rise in population suffering from HIV/AIDS, discovery and advancement of pipeline drugs and facilities provided by hospitals in intensive care units for those who have undergone surgery, surge in chemotherapy and increase in use of broad spectrum antibiotics and global economic growth is going to accelerate the invasive fungal infection market. Introduction of advanced medicines has already proven to be constructive as it directly improves the health of immuno-compromised patient and enhances the life expectancy of a patient.
The Invasive Fungal Infection market has been estimated to witness growth in future primarily because of surging demand for low-cost pipeline products and increase in use of broad-spectrum antibiotics which makes fungi resistant to various medicines and to opt for the low-cost medicines whose effect can last longer than the traditional medicines.
A number of companies are offering variety of antibiotics which have decreased the resistance of several medicines, thus increasing the incidence of invasive fungal infection. In addition, rising investment by major leading Invasive Antifungal manufacturers in various regions with demand for effective and low cost product and focus of government on educating people about the care taken during the stay in ICU after undergoing solid organ transplantation with various government powered awareness programs that are being run with an aim to eradicate diseases, has been anticipated to spur the market growth during the forecast period.
SCOPE OF THE REPORT
Global Invasive Fungal Infection Market was valued at USD 6103.5 Million in the year 2018. The rise in population suffering from HIV/AIDS, discovery and advancement of pipeline drugs and facilities provided by hospitals in intensive care units for those who have undergone surgery, surge in chemotherapy and increase in use of broad spectrum antibiotics and global economic growth is going to accelerate the invasive fungal infection market. Introduction of advanced medicines has already proven to be constructive as it directly improves the health of immuno-compromised patient and enhances the life expectancy of a patient.
The Invasive Fungal Infection market has been estimated to witness growth in future primarily because of surging demand for low-cost pipeline products and increase in use of broad-spectrum antibiotics which makes fungi resistant to various medicines and to opt for the low-cost medicines whose effect can last longer than the traditional medicines.
A number of companies are offering variety of antibiotics which have decreased the resistance of several medicines, thus increasing the incidence of invasive fungal infection. In addition, rising investment by major leading Invasive Antifungal manufacturers in various regions with demand for effective and low cost product and focus of government on educating people about the care taken during the stay in ICU after undergoing solid organ transplantation with various government powered awareness programs that are being run with an aim to eradicate diseases, has been anticipated to spur the market growth during the forecast period.
SCOPE OF THE REPORT
- There report analyzes the Global Invasive Fungal Infection Market By Diseases (Candidemia and invasive Candidiasis, Intra-abdominal candidiasis (Candida Peritonitis), Cryptococcal Meningitis, Histoplasmosis Disseminated, Histoplasmosis Acute Pulmonary, Invasive aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others).
- The Global Invasive Fungal Infection Market has been analysed By Region (North America, Europe, Asia Pacific, ROW) and By Country (United States, Canada, Germany, France, United Kingdom, Spain, China, South Korea, Japan, India).
- The key insights of the report have been presented through the frameworks of SWOT, Porter and Market Attractiveness charts. Market Attractiveness charts have been presented by diseases and by region. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report provides a detailed pipeline analysis of drugs being developed to cure the problem of Invasive Fungal Infection.
- The report tracks competitive developments,market share analysis, strategies and new product development. The companies analysed in the report include Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline, Bayer AG, Abott, Merck & Co., Astellas Pharma Inc., F2G – The Rare Fungal Disease Company, Scynexis Inc
- The report presents the analysis of Global Invasive Fungal Infection Market for the historical period of 2014-2018 and the forecast period of 2019-2024.
- Pharmaceutical Companies
- Consulting and Advisory Firms
- Medical Practitioners
- Regulatory Authorities
1. REPORT SCOPE & METHODOLOGY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
2.1 Both Healthcare Providers and Public Health Agencies to Improve Diagnostics
2.2 Escalate the awareness among the population of APAC region
3. GLOBAL INVASIVE FUNGAL INFECTION PRODUCT OUTLOOK
4. GLOBAL INVASIVE FUNGAL INFECTION MARKET: SIZING, GROWTH, FORECAST
4.1 Market Size, By Value, Year 2014-2024
5. GLOBAL INVASIVE FUNGAL INFECTION MARKET SEGMENTATION BY DISEASES
5.1 Competitive Scenario of Global Invasive Fungal Infection Market: By Diseases
5.2 Candidaemia and invasive candiasis – Market Size and Forecast (2019-2024)
5.3 Intra-abdominal Candiasis (Candida Peritonitis) - Market Size and Forecast (2019-2024)
5.4 Cryptococcal Meningitis – Market Size and Forecast (2019-2024)
5.5 Histoplasmosis Disseminated- Market Size and Forecast (2019-2024)
5.6 Histoplasmosis acute pulmonary – Market Size and Forecast (2019-2024)
5.7 Invasive Aspergillosis - Market Size and Forecast (2019-2024)
5.8 Invasive Rhinosinusitis – Market Size and Forecast (2019-2024)
5.9 Mucormycosis - Market Size and Forecast (2019-2024)
5.10 Pneumocystis Pneumonia - Market Size and Forecast (2019-2024)
5.11 Others – Market Size and Forecast (2019-2024)
6. GLOBAL INVASIVE FUNGAL INFECTION MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Invasive Fungal Infection: By Region
7. NORTH AMERICA INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
7.1 North America Invasive Fungal Infection Market: Size and Forecast (2019-2024)
7.2 North America Invasive Fungal Infection Market – Prominent Companies
7.3 Market Segmentation By Product Type- (Diseases)
7.4 Market Segmentation By Diseases (Candidemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
7.5 North America Invasive Fungal Infection Market: Country Analysis
7.6 Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024)
7.7 Competitive Scenario of North America Invasive Fungal Infection: By Country
7.8 United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
7.9 United States Invasive Fungal Infection Market Segmentation- By Diseases
7.10 Canada Invasive Fungal Infection Market: Size and Forecast (2019-2024)
7.11 Canada Invasive Fungal Infection Market Segmentation- By Diseases
8. EUROPE INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
8.1 Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value
(Year-2024)
8.2 Competitive Scenario of Europe Invasive Fungal Infection: By Country
8.3 Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.4 Europe Invasive Fungal Infection Market – Prominent Companies
8.5 Market Segmentation By Diseases- (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
8.6 Europe Invasive Fungal Infection Market: Country Analysis
8.7 Germany Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.8 Germany Invasive Fungal Infection Market Segmentation- By Diseases
8.9 France Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.10 France Invasive Fungal Infection Market Segmentation- By Diseases
8.11 United Kingdom Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.12 United Kingdom Invasive Fungal Infection Market Segmentation- By Diseases
8.13 Spain Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.14 Spain Invasive Fungal Infection Market Segmentation- By Diseases
8.15 Rest of Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.16 Rest of Europe Invasive Fungal Infection Market Segmentation- By Product Type, End User
9. ASIA PACIFIC INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
9.1 Market Opportunity Chart of Asia Pacific Invasive Fungal Infection Market - By Country, By Value
(Year-2024)
9.2 Competitive Scenario of Asia Pacific Invasive Fungal Infection: By Country
9.3 Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.4 Asia Pacific Invasive Fungal Infection Market – Prominent Companies
9.5 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
9.6 Asia Pacific Invasive Fungal Infection Market: Country Analysis
9.7 China Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.8 China Invasive Fungal Infection Market Segmentation- By Diseases
9.9 South Korea Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.10 South Korea Invasive Fungal Infection Market Segmentation- By Diseases
9.11 Japan Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.12 Japan Invasive Fungal Infection Market Segmentation- By Diseases
9.13 India Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.14 India Invasive Fungal Infection Market Segmentation- By Diseases
9.15 Rest of Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.16 Rest of Asia Pacific Invasive Fungal Infection Market Segmentation- By Diseases
10. REST OF THE WORLD INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
10.1 Market Opportunity Chart of Rest of the World Invasive Fungal Infection Market - By Country, By Value
(Year-2024)
10.2 Competitive Scenario of Rest of the World Invasive Fungal Infection: By Country
10.3 Rest of the World Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.4 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
10.5 Rest of the World Invasive Fungal Infection Market: Country Analysis
10.6 Brazil Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.7 Brazil Invasive Fungal Infection Market Segmentation- By Diseases
10.8 Egypt Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.9 Egypt Invasive Fungal Infection Market Segmentation- By Diseases
10.10 Rest of the Countries Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.11 Rest of the Countries Invasive Fungal Infection Market Segmentation- By Diseases
11. GLOBAL INVASIVE FUNGAL INFECTION MARKET DYNAMICS
11.1 Global Invasive Fungal Infection Market Drivers
11.2 Global Invasive Fungal Infection Market Restraints
11.3 Global Invasive Fungal Infection Market Trends
12. PIPELINE DRUGS ANALYSIS - INVASIVE FUNGAL INFECTION
13. MARKET ATTRACTIVENESS AND STRATEGIC ANALYSIS
13.1.1 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases(Year 2024)
13.1.2 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Region (Year 2024)
14. COMPETITIVE LANDSCAPE
14.1 Market Share Analysis
14.2 SWOT Analysis
14.3 Porter’s Five Force Analysis
15. COMPANY ANALYSIS (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)
15.1 Cidara Therapeutics
15.2 Basilea Pharmaceutica
15.3 Pfizer
15.4 GlaxoSmithKline
15.5 Bayer AG
15.6 Abbott
15.7 Merck & Co
15.8 Astellas Pharma Inc.
15.9 F2G- the Rare Fungal Disease Company
15.10 Scynexis Inc.
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
2.1 Both Healthcare Providers and Public Health Agencies to Improve Diagnostics
2.2 Escalate the awareness among the population of APAC region
3. GLOBAL INVASIVE FUNGAL INFECTION PRODUCT OUTLOOK
4. GLOBAL INVASIVE FUNGAL INFECTION MARKET: SIZING, GROWTH, FORECAST
4.1 Market Size, By Value, Year 2014-2024
5. GLOBAL INVASIVE FUNGAL INFECTION MARKET SEGMENTATION BY DISEASES
5.1 Competitive Scenario of Global Invasive Fungal Infection Market: By Diseases
5.2 Candidaemia and invasive candiasis – Market Size and Forecast (2019-2024)
5.3 Intra-abdominal Candiasis (Candida Peritonitis) - Market Size and Forecast (2019-2024)
5.4 Cryptococcal Meningitis – Market Size and Forecast (2019-2024)
5.5 Histoplasmosis Disseminated- Market Size and Forecast (2019-2024)
5.6 Histoplasmosis acute pulmonary – Market Size and Forecast (2019-2024)
5.7 Invasive Aspergillosis - Market Size and Forecast (2019-2024)
5.8 Invasive Rhinosinusitis – Market Size and Forecast (2019-2024)
5.9 Mucormycosis - Market Size and Forecast (2019-2024)
5.10 Pneumocystis Pneumonia - Market Size and Forecast (2019-2024)
5.11 Others – Market Size and Forecast (2019-2024)
6. GLOBAL INVASIVE FUNGAL INFECTION MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Invasive Fungal Infection: By Region
7. NORTH AMERICA INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
7.1 North America Invasive Fungal Infection Market: Size and Forecast (2019-2024)
7.2 North America Invasive Fungal Infection Market – Prominent Companies
7.3 Market Segmentation By Product Type- (Diseases)
7.4 Market Segmentation By Diseases (Candidemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
7.5 North America Invasive Fungal Infection Market: Country Analysis
7.6 Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024)
7.7 Competitive Scenario of North America Invasive Fungal Infection: By Country
7.8 United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
7.9 United States Invasive Fungal Infection Market Segmentation- By Diseases
7.10 Canada Invasive Fungal Infection Market: Size and Forecast (2019-2024)
7.11 Canada Invasive Fungal Infection Market Segmentation- By Diseases
8. EUROPE INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
8.1 Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value
(Year-2024)
8.2 Competitive Scenario of Europe Invasive Fungal Infection: By Country
8.3 Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.4 Europe Invasive Fungal Infection Market – Prominent Companies
8.5 Market Segmentation By Diseases- (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
8.6 Europe Invasive Fungal Infection Market: Country Analysis
8.7 Germany Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.8 Germany Invasive Fungal Infection Market Segmentation- By Diseases
8.9 France Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.10 France Invasive Fungal Infection Market Segmentation- By Diseases
8.11 United Kingdom Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.12 United Kingdom Invasive Fungal Infection Market Segmentation- By Diseases
8.13 Spain Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.14 Spain Invasive Fungal Infection Market Segmentation- By Diseases
8.15 Rest of Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024)
8.16 Rest of Europe Invasive Fungal Infection Market Segmentation- By Product Type, End User
9. ASIA PACIFIC INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
9.1 Market Opportunity Chart of Asia Pacific Invasive Fungal Infection Market - By Country, By Value
(Year-2024)
9.2 Competitive Scenario of Asia Pacific Invasive Fungal Infection: By Country
9.3 Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.4 Asia Pacific Invasive Fungal Infection Market – Prominent Companies
9.5 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
9.6 Asia Pacific Invasive Fungal Infection Market: Country Analysis
9.7 China Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.8 China Invasive Fungal Infection Market Segmentation- By Diseases
9.9 South Korea Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.10 South Korea Invasive Fungal Infection Market Segmentation- By Diseases
9.11 Japan Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.12 Japan Invasive Fungal Infection Market Segmentation- By Diseases
9.13 India Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.14 India Invasive Fungal Infection Market Segmentation- By Diseases
9.15 Rest of Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024)
9.16 Rest of Asia Pacific Invasive Fungal Infection Market Segmentation- By Diseases
10. REST OF THE WORLD INVASIVE FUNGAL INFECTION MARKET: SEGMENTATION BY DISEASES (2019-2024)
10.1 Market Opportunity Chart of Rest of the World Invasive Fungal Infection Market - By Country, By Value
(Year-2024)
10.2 Competitive Scenario of Rest of the World Invasive Fungal Infection: By Country
10.3 Rest of the World Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.4 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others)
10.5 Rest of the World Invasive Fungal Infection Market: Country Analysis
10.6 Brazil Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.7 Brazil Invasive Fungal Infection Market Segmentation- By Diseases
10.8 Egypt Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.9 Egypt Invasive Fungal Infection Market Segmentation- By Diseases
10.10 Rest of the Countries Invasive Fungal Infection Market: Size and Forecast (2019-2024)
10.11 Rest of the Countries Invasive Fungal Infection Market Segmentation- By Diseases
11. GLOBAL INVASIVE FUNGAL INFECTION MARKET DYNAMICS
11.1 Global Invasive Fungal Infection Market Drivers
11.2 Global Invasive Fungal Infection Market Restraints
11.3 Global Invasive Fungal Infection Market Trends
12. PIPELINE DRUGS ANALYSIS - INVASIVE FUNGAL INFECTION
13. MARKET ATTRACTIVENESS AND STRATEGIC ANALYSIS
13.1.1 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases(Year 2024)
13.1.2 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Region (Year 2024)
14. COMPETITIVE LANDSCAPE
14.1 Market Share Analysis
14.2 SWOT Analysis
14.3 Porter’s Five Force Analysis
15. COMPANY ANALYSIS (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)
15.1 Cidara Therapeutics
15.2 Basilea Pharmaceutica
15.3 Pfizer
15.4 GlaxoSmithKline
15.5 Bayer AG
15.6 Abbott
15.7 Merck & Co
15.8 Astellas Pharma Inc.
15.9 F2G- the Rare Fungal Disease Company
15.10 Scynexis Inc.
LIST OF FIGURES
Figure 1: Global Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 2: Global Prevalence of HIV, (%), 2013–2017
Figure 3: Global Deaths by HIV, (%), 2013–2017
Figure 4: Global Prevalence of Neoplasms (%), 2014–2016
Figure 5: Global Prevalence of Tuberculosis (%), 2015–2017
Figure 6: Competitive Scenario of Global Fungal Infection Market- BY Diseases
Figure 7: Global Invasive Fungal Infection Market- By Candidemia and invasive candiasis, By Value (USD Million), 2014-2024
Figure 8: Global Invasive Fungal Infection Market- By Intra-abdominal Candiasis (Candida Peritonitis), By Value (USD Million), 2014-2024
Figure 9: Global Invasive Fungal Infection Market- By Cryptococcal Meningitis , By Value (USD Million), 2014-2024
Figure 10: Global Invasive Fungal Infection Market- By Histoplasmosis Disseminated, By Value (USD Million), 2014-2024
Figure 11: Global Invasive Fungal Infection Market- By Histoplasmosis acute pulmonary, By Value (USD Million), 2014-2024
Figure 12: Global Invasive Fungal Infection Market- By Invasive Aspergillosis, By Value (USD Million), 2014-2024
Figure 13: Global Invasive Fungal Infection Market- By Invasive Rhinosinusitis, By Value (USD Million), 2014-2024
Figure 14: Global Invasive Fungal Infection Market- By Mucormycosis, By Value (USD Million), 2014-2024
Figure 15: Global Invasive Fungal Infection Market- By Pneumocystis Pneumonia, By Value (USD Million), 2014-2024
Figure 16: Global Invasive Fungal Infection Market- By Others, By Value (USD Million), 2014-2024
Figure 17: Competitive Scenario of Global Invasive Fungal Infection- By Region
Figure 18: North America Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 19: North America Prevalence of HIV, (%), 2013–2017
Figure 20: North America Deaths by HIV, (%), 2013–2017
Figure 21: North America Prevalence of Neoplasms (%), 2013–2017
Figure 22: North America Prevalence of Tuberculosis (%), 2012–2017
Figure 23: North America Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 24: North America Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 25: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024)
Figure 26: Competitive Scenario of North America Invasive Fungal Infection- By Country
Figure 27: United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 28: US Prevalence of HIV, (%), 2013–2017
Figure 29: US Deaths by HIV, (%), 2013–2017
Figure 30: US Prevalence of Neoplasms (%), 2014–2016
Figure 31: US Prevalence of Tuberculosis (%), 2012–2017
Figure 32: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 33: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 34: Canada Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 35: Canada Prevalence of HIV, (%), 2013–2017
Figure 36: Canada Deaths by HIV, (%), 2013–2017
Figure 37: Canada Prevalence of Neoplasms (%), 2014–2016
Figure 38: Canada Prevalence of Tuberculosis (%), 2012–2017)
Figure 39: Canada Invasive Fungal Infection Market- By Diseases(USD Million), 2014-2024
Figure 40: Canada Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 41: Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value (Year 2024)
Figure 42: Competitive Scenario of Europe Invasive Fungal Infection – By Country
Figure 43: Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 44: Europe Prevalence of HIV, (%), 2013–2017
Figure 45: Europe Deaths by HIV, (%), 2013–2017
Figure 46: Europe Prevalence of Neoplasms (%), 2013–2017
Figure 47: Europe Prevalence of Tuberculosis (%), 2012–2017
Figure 48: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 49: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 50: Germany Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 51: Germany Prevalence of HIV, (%), 2013–2017
Figure 52: Germany Deaths by HIV, (%), 2013–2017)
Figure 53: Germany Prevalence of Neoplasms (%), 2013–2017
Figure 54: Germany Prevalence of Tuberculosis (%), 2012–2017
Figure 55: Germany Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 56: Germany Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 57: France Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 58: France Prevalence of HIV, (%), 2013–2017
Figure 59: France Deaths by HIV, (%), 2013–2017
Figure 60: France Prevalence of Neoplasms (%), 2013–2017
Figure 61: France Prevalence of Tuberculosis (%), 2012–2017
Figure 62: France Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 63: France Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 64: United Kingdom Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 65: UK Prevalence of HIV, (%), 2013–2017
Figure 66: UK Deaths by HIV, (%), 2013–2017
Figure 67: UK Prevalence of Neoplasms (%), 2013–2017
Figure 68: UK Prevalence of Tuberculosis (%), 2012–2017
Figure 69: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 70: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 71: Spain Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 72: Spain Prevalence of HIV, (%), 2013–2017
Figure 73: Spain Deaths by HIV, (%), 2013–2017
Figure 74: Spain Prevalence of Neoplasms (%), 2013–2017
Figure 75: Spain Prevalence of Tuberculosis (%), 2012–2017
Figure 76: Spain Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 77: Spain Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 78: Rest of Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 79: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 80: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 81: Market Opportunity Chart of APAC Invasive Fungal Infection Market – By Country, By Value
Figure 82: Competitive Scenario of APAC Invasive Fungal Infection – By Country
Figure 83: APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 84: Asia Prevalence of HIV, (%), 2013–2017
Figure 85: Asia Deaths by HIV, (%), 2013–2017
Figure 86: Asia Prevalence of Neoplasms (%), 2013–2017
Figure 87: Asia Prevalence of Tuberculosis (%), 2012–2017
Figure 88: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 89: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 90: China Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 91: China Prevalence of HIV, (%), 2013–2017
Figure 92: China Deaths by HIV, (%), 2013–2017
Figure 93: China Prevalence of Neoplasms (%), 2013–2017
Figure 94: China Prevalence of Tuberculosis (%), 2012–2017
Figure 95: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 96: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 97: South Korea Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 98: South Korea Prevalence of HIV, (%), 2013–2017
Figure 99: South Korea Deaths by HIV, (%), 2013–2017
Figure 100: South Korea Prevalence of Neoplasms (%), 2013–2017
Figure 101: South Korea Prevalence of Tuberculosis (%), 2012–2017
Figure 102: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 103: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 104: Japan Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 105: Japan Prevalence of HIV, (%), 2013–2017
Figure 106: Japan Incidence of HIV, (%), 2013–2017
Figure 107: Japan Prevalence of Neoplasms (%), 2013–2017
Figure 108: Japan Prevalence of Tuberculosis (%), 2012–2017
Figure 109: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 110: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 111: India Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 112: India Prevalence of HIV, (%), 2013–2017
Figure 113: India Incidence of HIV, (%), 2013–2017
Figure 114: India Prevalence of Neoplasms (%), 2013–2017
Figure 115: India Prevalence of Tuberculosis (%), 2012–2017
Figure 116: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 117: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 118: Rest of APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 119: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 120: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 121: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year 2024)
Figure 122: Competitive Scenario of Rest of the World Invasive Fungal Infection – By Country
Figure 123: Rest of the World Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 124: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 125: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 126: Brazil Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 127: Brazil Prevalence of HIV, (%), 2013–2017
Figure 128: Brazil deaths of HIV, (%), 2013–2017
Figure 129: Brazil Prevalence of Neoplasms (%), 2013–2017
Figure 130: Brazil Prevalence of Tuberculosis (%), 2012–2017
Figure 131: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 132: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 133: Egypt Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 134: Egypt Prevalence of HIV, (%), 2013–2017
Figure 135: Egypt Incidence of HIV, (%), 2013–2017
Figure 136: Egypt Prevalence of Neoplasms (%), 2013–2017
Figure 137: Egypt Prevalence of Tuberculosis (%), 2012–2017
Figure 138: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 139: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 140: Rest of the Countries Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 141: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 142: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 143: Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases (Year-2024)
Figure 144: Market Attractiveness Chart of Global Invasive Fungal Infection Market – By Region, By Value, (Year-204)
Figure 145: Competitive Positions of Invasive Fungal Infection Companies (2018)
Figure 146: Cidara Therapeutics, Research and Development 2016-2018 (In USD Million)
Figure 147: Cidara Therapeutics, Research and Development By Product Category, 2018 (In %)
Figure 148: Basilea Revenue, 2014-2018 (In USD Billion)
Figure 149: Basilea Revenue, By Region, 2017 (In %)
Figure 150: Basilea Revenue, By Region, 2018 (In %)
Figure 151: Pfizer Revenue, 2014 - 2018 (In USD Billion)
Figure 152: Pfizer Sales Revenue, By Region, 2017 (In %)
Figure 153: Pfizer Sales Revenue, By Region, 2018 (In %)
Figure 154: Pfizer Revenue, By Business Segment, 2017, 2018 (In USD Million)
Figure 155: Pfizer Revenue, By IH Segment, By Region 2018 (In %)
Figure 156: Pfizer Revenue, By EH Segment, By Region 2018 (In %)
Figure 157: GSK, Turnover, 2014 - 2018 (In USD Billion)
Figure 158: GSK, Turnover, By Segments, 2017 (In %)
Figure 159: GSK, Turnover, By Segments, 2018 (In %)
Figure 160: GSK, Turnover, By Geographic Region, 2017 (In %)
Figure 161: GSK, Turnover, By Geographic Region, 2018 (In %)
Figure 162: Bayer AG, Sales Revenue, 2014 - 2018 (In USD Million)
Figure 163: Bayer AG, Net Sales Revenue, By Region, 2017 (In %)
Figure 164: Bayer AG, Net Sales Revenue, By Region, 2018 (In %)
Figure 165: Abbott Net Income, 2014 - 2018 (In USD Million)
Figure 166: Abbott Sales Revenue, By Business Segment, 2017 (In %)
Figure 167: Abbott Sales Revenue, By Business Segment, 2018 (In %)
Figure 168: Abbott Sales, By Geographic Region, 2017 (In %)
Figure 169: Abbott Sales, By Geographic Region, 2018 (In %)
Figure 170: Merck & Co, Sales, 2014 - 2018 (In USD Million)
Figure 171: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2017 (In %)
Figure 172: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2018 (In %)
Figure 173: Merck & Co, Sales, By Geographic Region, 2017 (In %)
Figure 174: Merck & Co, Sales, By Geographic Region, 2018 (In %)
Figure 174: Astellas Pharma Inc., Sales, 2014 - 2018 (In USD Billion)
Figure 176: Astellas Pharma Inc., Sales Revenue, By Product, 2018 (In USD Billion)
Figure 177: Astellas Pharma Inc., Sales Revenue, By Product, 2019 (In USD Billion)
Figure 178: Astellas Pharma Inc. , Sales, By Geographic Region, 2017 (In %)
Figure 179: Astellas Pharma Inc. , Sales, By Geographic Region, 2018 (In %)
Figure 180: SCYNEXIS Inc., Revenue, 2014 - 2018 (In USD Thousands)
Figure 1: Global Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 2: Global Prevalence of HIV, (%), 2013–2017
Figure 3: Global Deaths by HIV, (%), 2013–2017
Figure 4: Global Prevalence of Neoplasms (%), 2014–2016
Figure 5: Global Prevalence of Tuberculosis (%), 2015–2017
Figure 6: Competitive Scenario of Global Fungal Infection Market- BY Diseases
Figure 7: Global Invasive Fungal Infection Market- By Candidemia and invasive candiasis, By Value (USD Million), 2014-2024
Figure 8: Global Invasive Fungal Infection Market- By Intra-abdominal Candiasis (Candida Peritonitis), By Value (USD Million), 2014-2024
Figure 9: Global Invasive Fungal Infection Market- By Cryptococcal Meningitis , By Value (USD Million), 2014-2024
Figure 10: Global Invasive Fungal Infection Market- By Histoplasmosis Disseminated, By Value (USD Million), 2014-2024
Figure 11: Global Invasive Fungal Infection Market- By Histoplasmosis acute pulmonary, By Value (USD Million), 2014-2024
Figure 12: Global Invasive Fungal Infection Market- By Invasive Aspergillosis, By Value (USD Million), 2014-2024
Figure 13: Global Invasive Fungal Infection Market- By Invasive Rhinosinusitis, By Value (USD Million), 2014-2024
Figure 14: Global Invasive Fungal Infection Market- By Mucormycosis, By Value (USD Million), 2014-2024
Figure 15: Global Invasive Fungal Infection Market- By Pneumocystis Pneumonia, By Value (USD Million), 2014-2024
Figure 16: Global Invasive Fungal Infection Market- By Others, By Value (USD Million), 2014-2024
Figure 17: Competitive Scenario of Global Invasive Fungal Infection- By Region
Figure 18: North America Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 19: North America Prevalence of HIV, (%), 2013–2017
Figure 20: North America Deaths by HIV, (%), 2013–2017
Figure 21: North America Prevalence of Neoplasms (%), 2013–2017
Figure 22: North America Prevalence of Tuberculosis (%), 2012–2017
Figure 23: North America Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 24: North America Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 25: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024)
Figure 26: Competitive Scenario of North America Invasive Fungal Infection- By Country
Figure 27: United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 28: US Prevalence of HIV, (%), 2013–2017
Figure 29: US Deaths by HIV, (%), 2013–2017
Figure 30: US Prevalence of Neoplasms (%), 2014–2016
Figure 31: US Prevalence of Tuberculosis (%), 2012–2017
Figure 32: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 33: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 34: Canada Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 35: Canada Prevalence of HIV, (%), 2013–2017
Figure 36: Canada Deaths by HIV, (%), 2013–2017
Figure 37: Canada Prevalence of Neoplasms (%), 2014–2016
Figure 38: Canada Prevalence of Tuberculosis (%), 2012–2017)
Figure 39: Canada Invasive Fungal Infection Market- By Diseases(USD Million), 2014-2024
Figure 40: Canada Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 41: Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value (Year 2024)
Figure 42: Competitive Scenario of Europe Invasive Fungal Infection – By Country
Figure 43: Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 44: Europe Prevalence of HIV, (%), 2013–2017
Figure 45: Europe Deaths by HIV, (%), 2013–2017
Figure 46: Europe Prevalence of Neoplasms (%), 2013–2017
Figure 47: Europe Prevalence of Tuberculosis (%), 2012–2017
Figure 48: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 49: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 50: Germany Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 51: Germany Prevalence of HIV, (%), 2013–2017
Figure 52: Germany Deaths by HIV, (%), 2013–2017)
Figure 53: Germany Prevalence of Neoplasms (%), 2013–2017
Figure 54: Germany Prevalence of Tuberculosis (%), 2012–2017
Figure 55: Germany Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 56: Germany Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 57: France Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 58: France Prevalence of HIV, (%), 2013–2017
Figure 59: France Deaths by HIV, (%), 2013–2017
Figure 60: France Prevalence of Neoplasms (%), 2013–2017
Figure 61: France Prevalence of Tuberculosis (%), 2012–2017
Figure 62: France Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 63: France Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 64: United Kingdom Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 65: UK Prevalence of HIV, (%), 2013–2017
Figure 66: UK Deaths by HIV, (%), 2013–2017
Figure 67: UK Prevalence of Neoplasms (%), 2013–2017
Figure 68: UK Prevalence of Tuberculosis (%), 2012–2017
Figure 69: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 70: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 71: Spain Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 72: Spain Prevalence of HIV, (%), 2013–2017
Figure 73: Spain Deaths by HIV, (%), 2013–2017
Figure 74: Spain Prevalence of Neoplasms (%), 2013–2017
Figure 75: Spain Prevalence of Tuberculosis (%), 2012–2017
Figure 76: Spain Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 77: Spain Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 78: Rest of Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 79: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 80: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 81: Market Opportunity Chart of APAC Invasive Fungal Infection Market – By Country, By Value
Figure 82: Competitive Scenario of APAC Invasive Fungal Infection – By Country
Figure 83: APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 84: Asia Prevalence of HIV, (%), 2013–2017
Figure 85: Asia Deaths by HIV, (%), 2013–2017
Figure 86: Asia Prevalence of Neoplasms (%), 2013–2017
Figure 87: Asia Prevalence of Tuberculosis (%), 2012–2017
Figure 88: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 89: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 90: China Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 91: China Prevalence of HIV, (%), 2013–2017
Figure 92: China Deaths by HIV, (%), 2013–2017
Figure 93: China Prevalence of Neoplasms (%), 2013–2017
Figure 94: China Prevalence of Tuberculosis (%), 2012–2017
Figure 95: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 96: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024
Figure 97: South Korea Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 98: South Korea Prevalence of HIV, (%), 2013–2017
Figure 99: South Korea Deaths by HIV, (%), 2013–2017
Figure 100: South Korea Prevalence of Neoplasms (%), 2013–2017
Figure 101: South Korea Prevalence of Tuberculosis (%), 2012–2017
Figure 102: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 103: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 104: Japan Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 105: Japan Prevalence of HIV, (%), 2013–2017
Figure 106: Japan Incidence of HIV, (%), 2013–2017
Figure 107: Japan Prevalence of Neoplasms (%), 2013–2017
Figure 108: Japan Prevalence of Tuberculosis (%), 2012–2017
Figure 109: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 110: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 111: India Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 112: India Prevalence of HIV, (%), 2013–2017
Figure 113: India Incidence of HIV, (%), 2013–2017
Figure 114: India Prevalence of Neoplasms (%), 2013–2017
Figure 115: India Prevalence of Tuberculosis (%), 2012–2017
Figure 116: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 117: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 118: Rest of APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 119: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 120: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 121: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year 2024)
Figure 122: Competitive Scenario of Rest of the World Invasive Fungal Infection – By Country
Figure 123: Rest of the World Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 124: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 125: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 126: Brazil Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 127: Brazil Prevalence of HIV, (%), 2013–2017
Figure 128: Brazil deaths of HIV, (%), 2013–2017
Figure 129: Brazil Prevalence of Neoplasms (%), 2013–2017
Figure 130: Brazil Prevalence of Tuberculosis (%), 2012–2017
Figure 131: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 132: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 133: Egypt Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 134: Egypt Prevalence of HIV, (%), 2013–2017
Figure 135: Egypt Incidence of HIV, (%), 2013–2017
Figure 136: Egypt Prevalence of Neoplasms (%), 2013–2017
Figure 137: Egypt Prevalence of Tuberculosis (%), 2012–2017
Figure 138: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 139: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 140: Rest of the Countries Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million)
Figure 141: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 142: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024
Figure 143: Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases (Year-2024)
Figure 144: Market Attractiveness Chart of Global Invasive Fungal Infection Market – By Region, By Value, (Year-204)
Figure 145: Competitive Positions of Invasive Fungal Infection Companies (2018)
Figure 146: Cidara Therapeutics, Research and Development 2016-2018 (In USD Million)
Figure 147: Cidara Therapeutics, Research and Development By Product Category, 2018 (In %)
Figure 148: Basilea Revenue, 2014-2018 (In USD Billion)
Figure 149: Basilea Revenue, By Region, 2017 (In %)
Figure 150: Basilea Revenue, By Region, 2018 (In %)
Figure 151: Pfizer Revenue, 2014 - 2018 (In USD Billion)
Figure 152: Pfizer Sales Revenue, By Region, 2017 (In %)
Figure 153: Pfizer Sales Revenue, By Region, 2018 (In %)
Figure 154: Pfizer Revenue, By Business Segment, 2017, 2018 (In USD Million)
Figure 155: Pfizer Revenue, By IH Segment, By Region 2018 (In %)
Figure 156: Pfizer Revenue, By EH Segment, By Region 2018 (In %)
Figure 157: GSK, Turnover, 2014 - 2018 (In USD Billion)
Figure 158: GSK, Turnover, By Segments, 2017 (In %)
Figure 159: GSK, Turnover, By Segments, 2018 (In %)
Figure 160: GSK, Turnover, By Geographic Region, 2017 (In %)
Figure 161: GSK, Turnover, By Geographic Region, 2018 (In %)
Figure 162: Bayer AG, Sales Revenue, 2014 - 2018 (In USD Million)
Figure 163: Bayer AG, Net Sales Revenue, By Region, 2017 (In %)
Figure 164: Bayer AG, Net Sales Revenue, By Region, 2018 (In %)
Figure 165: Abbott Net Income, 2014 - 2018 (In USD Million)
Figure 166: Abbott Sales Revenue, By Business Segment, 2017 (In %)
Figure 167: Abbott Sales Revenue, By Business Segment, 2018 (In %)
Figure 168: Abbott Sales, By Geographic Region, 2017 (In %)
Figure 169: Abbott Sales, By Geographic Region, 2018 (In %)
Figure 170: Merck & Co, Sales, 2014 - 2018 (In USD Million)
Figure 171: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2017 (In %)
Figure 172: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2018 (In %)
Figure 173: Merck & Co, Sales, By Geographic Region, 2017 (In %)
Figure 174: Merck & Co, Sales, By Geographic Region, 2018 (In %)
Figure 174: Astellas Pharma Inc., Sales, 2014 - 2018 (In USD Billion)
Figure 176: Astellas Pharma Inc., Sales Revenue, By Product, 2018 (In USD Billion)
Figure 177: Astellas Pharma Inc., Sales Revenue, By Product, 2019 (In USD Billion)
Figure 178: Astellas Pharma Inc. , Sales, By Geographic Region, 2017 (In %)
Figure 179: Astellas Pharma Inc. , Sales, By Geographic Region, 2018 (In %)
Figure 180: SCYNEXIS Inc., Revenue, 2014 - 2018 (In USD Thousands)
LIST OF TABLES
Table A Prominent Invasive Fungal Infection Companies Operated in North America Market
Table B Prominent Invasive Fungal Infection Companies Operated in Europe Market
Table C Prominent Invasive Fungal Infection Companies Operated in APAC Market
Table A Prominent Invasive Fungal Infection Companies Operated in North America Market
Table B Prominent Invasive Fungal Infection Companies Operated in Europe Market
Table C Prominent Invasive Fungal Infection Companies Operated in APAC Market
